Colombia has confirmed its fifth imported measles case in 2026, involving a 24-year-old woman who contracted the virus during travel to the United States, according to the Ministry of Health and Social Protection. This case underscores persistent gaps in global measles immunity despite widespread vaccine availability, with the individual having received only one dose of the MMR vaccine in childhood. As of April 2026, the Pan American Health Organization reports 127 confirmed measles cases across the Americas, 89% linked to international travel, highlighting the virus’s continued threat in regions with suboptimal vaccination coverage. Public health officials emphasize that two doses of the MMR vaccine are 97% effective at preventing measles and urge travelers to verify immunization status before international trips.
Understanding Measles Transmission and Vaccine-Induced Immunity
Measles, caused by the measles morbillivirus, spreads through respiratory droplets when an infected person coughs or sneezes, with the virus capable of remaining infectious in the air for up to two hours. The basic reproduction number (R0) for measles ranges from 12 to 18, meaning one infected individual can transmit the virus to 12–18 susceptible people in an unvaccinated population—among the highest of any known pathogen. The MMR vaccine contains live attenuated strains of measles, mumps, and rubella viruses, which stimulate the immune system to produce neutralizing antibodies without causing disease. After two doses, approximately 99% of recipients develop lifelong immunity to measles, though waning immunity can occur in a small subset of individuals, particularly those vaccinated before 12 months of age.
In Plain English: The Clinical Takeaway
- Two doses of the MMR vaccine provide nearly complete protection against measles, and a single dose leaves about 3% of people vulnerable.
- Measles is exceptionally contagious—more so than influenza or COVID-19—and can spread before symptoms appear.
- If you develop fever, cough, runny nose, and a red rash after international travel, seek medical care immediately and avoid public spaces.
Regional Vaccination Gaps and Health System Response
Colombia’s national immunization program reports that 91% of children received the first dose of MMR by age 1 in 2025, but only 85% completed the second dose by age 5—below the 95% threshold needed for herd immunity. This gap is particularly pronounced in rural departments like Chocó and La Guajira, where access to routine vaccination remains inconsistent. In response, the Ministry of Health has activated enhanced surveillance at airports and border crossings, deployed mobile vaccination units to high-risk municipalities, and issued travel advisories urging citizens to verify their MMR status before visiting countries with ongoing measles transmission, including the United States, where 58 cases were reported in the first quarter of 2026 according to the CDC. The Pan American Health Organization has pledged technical support to strengthen Colombia’s outbreak response, including laboratory confirmation capacity and contact tracing training.
“Imported measles cases like this one in Colombia are preventable tragedies that reveal weaknesses in global immunization systems. We must ensure that everyone, regardless of geography, has access to two lifesaving doses of the MMR vaccine.”
Measles Pathophysiology and Clinical Progression
Following inhalation, the measles virus infects immune cells in the respiratory tract and migrates to lymphoid tissue, where it replicates before entering the bloodstream—a phase known as viremia. This systemic spread triggers the characteristic symptoms: high fever (often exceeding 40°C), cough, coryza (runny nose), conjunctivitis, and Koplik spots—small white lesions on the buccal mucosa that appear 2–3 days before the rash. The maculopapular rash typically begins on the face and spreads downward to the trunk and extremities over 3–4 days. Complications occur in approximately 30% of cases, including pneumonia (the leading cause of measles-related death), encephalitis (in 1 per 1,000 cases), and subacute sclerosing panencephalitis (SSPE), a rare but fatal neurodegenerative disorder that may develop years after infection. Vitamin A supplementation is recommended by the WHO for all children with measles in low-resource settings, as it reduces mortality by up to 50% by mitigating epithelial damage and supporting immune function.
| Complication | Frequency | Key Risk Factors |
|---|---|---|
| Pneumonia | 1–6% of cases | Children <5 years, immunocompromised individuals |
| Encephalitis | 0.1% of cases | Occurs during or shortly after rash onset |
| SSPE | 4–11 per 100,000 cases | Infection before age 2; latent period of 6–10 years |
| Death | 0.1–0.2% in high-income countries | Malnutrition, vitamin A deficiency, delayed care |
Contraindications & When to Consult a Doctor
The MMR vaccine is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to a prior dose or to any vaccine component, including gelatin or neomycin. It should not be administered to pregnant women or those with severe immunodeficiency (e.g., from chemotherapy, congenital T-cell disorders, or advanced HIV/AIDS), as the live attenuated virus may cause uncontrolled infection. Individuals with mild illness, such as a low-grade fever or upper respiratory infection, may still be vaccinated. Anyone experiencing fever above 38.5°C lasting more than 72 hours, persistent cough, difficulty breathing, or a worsening rash after potential measles exposure should seek immediate medical evaluation. Pregnant women who suspect measles exposure should contact their obstetrician promptly, as infection increases the risk of preterm labor and low birth weight.
“In outbreak settings, timely administration of immunoglobulin within six days of exposure can prevent or modify measles in high-risk individuals who cannot receive the vaccine, such as pregnant women or the immunocompromised.”
Global Context and the Path to Elimination
The Region of the Americas was declared free of endemic measles transmission in 2016, but importations from regions with ongoing circulation—such as parts of Europe, Africa, and Asia—continue to pose a risk. In 2025, the European Centre for Disease Prevention and Control reported over 10,000 measles cases across the EU/EEA, driven by declining vaccination rates in several countries. The Measles & Rubella Initiative, a partnership led by the American Red Cross, CDC, UNICEF, WHO, and the United Nations Foundation, has supported vaccination campaigns that delivered over 2.9 billion doses of measles-containing vaccines since 2000, preventing an estimated 57 million deaths. Sustained investment in cold chain logistics, vaccine confidence initiatives, and rapid outbreak response remains critical to achieving and maintaining global measles elimination.
References
- World Health Organization. Measles. Https://www.who.int/news-room/fact-sheets/detail/measles
- Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Https://www.cdc.gov/measles/cases-outbreaks.html
- Pan American Health Organization. Epidemiological Alert: Measles. Https://www.paho.org/en/epi-alerts/measles
- Miller E, et al. Safety and efficacy of measles-containing vaccines. Vaccine. 2019;37(42):6275–6283. Https://doi.org/10.1016/j.vaccine.2019.08.062
- Gastañaduy PA, et al. Measles—United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(10):347–352. Https://doi.org/10.15585/mmwr.mm7010a2
